86
Participants
Start Date
August 31, 2010
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
AIN457
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
Placebo
Matching placebo to AIN457
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Bern
Novartis Investigative Site, Bern
Novartis Investigative Site, Lucerne
Novartis Investigative Site, Zurich
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Berlin
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Kiel
Novartis Investigative Site, Madrid
Novartis Investigative Site, Charlotte
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Louisville
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Arlington
Novartis Investigative Site, Houston
Novartis Investigative Site, Beverly Hills
Novartis Investigative Site, Portland
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Jerusalem
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Cambridge
Novartis Investigative Site, Teaneck
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Liverpool
Novartis Investigative Site, London
Novartis Investigative Site, York
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY